BTRX-246040, also known as LY-2940094, is a
potent and
selective nociceptin receptor antagonist which is under development by BlackThorn Therapeutics and
Eli Lilly for the treatment of
major depressive disorder
Major depressive disorder (MDD), also known as clinical depression, is a mental disorder characterized by at least two weeks of pervasive low mood, low self-esteem, and loss of interest or pleasure in normally enjoyable activities. Intro ...
(MDD).
It has demonstrated proof-of-concept clinical efficacy for depression.
As of 2017, it is in
phase II clinical trial
Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, diet ...
s for the treatment of MDD.
It was also under investigation for the treatment of
alcoholism
Alcoholism is, broadly, any drinking of alcohol that results in significant mental or physical health problems. Because there is disagreement on the definition of the word ''alcoholism'', it is not a recognized diagnostic entity. Predomi ...
, and similarly reached phase II clinical studies for this indication, but development was discontinued.
See also
*
List of investigational antidepressants
*
J-113,397
*
JTC-801
JTC-801 is an opioid analgesic drug used in scientific research.
JTC-801 is a selective antagonist for the nociceptin receptor, also known as the ORL-1 receptor. This was the fourth opioid receptor to be discovered and is still the least underst ...
*
SB-612,111
SB-612,111 is an opioid receptor ligand which is a potent and selective antagonist for the nociceptin receptor (ORL-1), several times more potent than the older drug J-113,397. It does not have analgesic effects in its own right, but prevents the ...
References
External links
BTRX-246040 (LY-2940094) - AdisInsight
Nociceptin receptor antagonists
Synthetic opioids
{{Nervous-system-drug-stub